Welcome to our dedicated page for Qualigen Therapeutics SEC filings (Ticker: QLGN), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Reading a biotech 10-K is challenging enough; add the G-quadruplex science behind Qualigen Therapeutics and the task becomes daunting. SEC documents detail everything from QN-302 trial costs to shelf registrations that may dilute shares, yet investors still need quick answers about burn rate and upcoming milestones.
That’s where Stock Titan’s AI steps in. Our platform ingests every Qualigen Therapeutics SEC filing the moment it posts to EDGAR and delivers:
- Plain-English digests that make Qualigen Therapeutics annual report 10-K simplified a reality
- Line-item highlights in each Qualigen Therapeutics quarterly earnings report 10-Q filing, including R&D spend and cash runway
- Instant alerts for Qualigen Therapeutics Form 4 insider transactions real-time, helping you track executive confidence
- Context around every Qualigen Therapeutics 8-K material events explained, whether it’s a trial update or financing agreement
Searching for “Qualigen Therapeutics insider trading Form 4 transactions” or “Qualigen Therapeutics proxy statement executive compensation”? You’ll find them all here, complete with AI-generated summaries that spotlight dilution clauses, licensing royalties, and key risk factors. Need deeper insight? Our expert commentary ties clinical progress to market impact, giving you the edge when interpreting Qualigen Therapeutics earnings report filing analysis.
Stop sifting through technical jargon. With Stock Titan you’re understanding Qualigen Therapeutics SEC documents with AI—from executive stock sales to new ATM offerings—so you can make informed decisions faster.
Qualigen Therapeutics, Inc. (QLGN) reported a challenging quarter with limited cash and ongoing operating losses. The company had approximately $332,000 in cash and an accumulated deficit of $127.4 million. For the six months ended June 30, 2025 the company used $2.7 million in operating cash and $6.3 million for the year ended December 31, 2024. Loss from continuing operations was $4.33 million for the period versus $3.51 million in the prior comparative period. Short-term borrowings included $3.64 million from nine investors and additional promissory notes totaling $2.3 million. Subsequent to period end, the company closed a private placement in July 2025 raising net proceeds of $4.258 million, which management expects will provide liquidity through year-end. The filing discloses multiple convertible debentures, warrant re-pricings, preferred stock conversions, a 2024 reverse stock split, and a $468,000 loan loss reserve related to Marizyme notes.
Qualigen Therapeutics, Inc. filed a Form D reporting a completed Regulation D offering that raised $4,500,000 in equity securities. The offering consisted of convertible preferred stock that can convert into common shares and was conducted under Rule 506(b). The issuer reports 14 investors and indicates the total offering amount sold equals the offering amount, with $0 remaining to be sold. The company listed no sales commissions or finders' fees (estimated) and stated $0 of gross proceeds will be used for payments to named executive officers or directors (estimate). The issuer declined to disclose revenue/net asset size. The offering was not part of a business combination and the issuer named Univest Securities LLC as the associated broker-dealer.
Alpha Capital Anstalt has filed Amendment No. 2 to Schedule 13G for Qualigen Therapeutics (QLGN).
- Beneficial ownership: 36,434 common shares.
- Ownership percentage: 2.223 % of the 1,635,475 shares outstanding as of 18 Jul 2025.
- Voting & dispositive power: Sole power over all reported shares; no shared power.
- Filer details: Liechtenstein entity, address Altenbach 8, FL-9490 Vaduz.
- Purpose: Certified as a passive investment with no intent to influence control.
The update simply records Alpha Capital’s sub-5 % stake; it carries limited strategic or valuation implications for QLGN shareholders.
On 23 Jul 2025 Qualigen Therapeutics (Nasdaq:QLGN) received a Nasdaq notice that its stockholders’ equity, as reported in the 31 Mar 2025 Form 10-Q, fell below the $2.5 million minimum required by Listing Rule 5550(b)(1). On 24 Jul 2025 Nasdaq’s Office of the General Counsel granted an extension after reviewing the company’s compliance plan and a pro-forma balance sheet reflecting a $4.5 million private placement of Series A-3 preferred stock, which would raise equity above the threshold.
Nasdaq accepted the plan, giving the company up to 12 months to evidence sustained compliance. Management is working to maintain the Nasdaq Capital Market listing but offers no assurance of success. Supporting materials include a press release dated 28 Jul 2025 (Ex. 99.1) and an unaudited pro-forma balance sheet (Ex. 99.2).
Qualigen Therapeutics, Inc. (NASDAQ: QLGN) filed a Form 8-K announcing a board-level governance change effective June 20 2025. Independent director Robert B. Lim was appointed Chair of the Audit Committee, succeeding Graydon Bensler, who will remain a committee member. The board affirmed that Lim meets Nasdaq Rule 5605 and SEC Rule 10A-3 independence criteria and is deemed an “audit committee financial expert” under Regulation S-K Item 407(d)(5). The filing states there are no related-party transactions or special arrangements connected to Lim’s elevation. No other management changes, financial results, or transactions were disclosed.
FAQ
What is the current stock price of Qualigen Therapeutics (QLGN)?
What is the market cap of Qualigen Therapeutics (QLGN)?
